AnaptysBio (ANAB) has recently experienced a significant decline in share price, dropping 11.68% in one day and 7.96% over the week, despite strong year-to-date returns of 27.70% and a remarkable 202.90% increase over the past year. Currently trading at $57.40, analysts suggest this is below a target of $78.25. The company’s price-to-sales (P/S) ratio of 7x is higher than its fair ratio of 4.6x according to internal estimates, raising concerns about potential overvaluation as AnaptysBio is expected to remain unprofitable for the next few years. However, a DCF model suggests a fair value significantly higher at $467.25 per share, indicating a possible investment opportunity amid mixed market sentiment.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/a-look-at-anaptysbio-anab-valuation-after-recent-share-price
